Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
50.02%
Operating Margin
45.05%
Net Margin
5.82%
Efficiency Metrics
Revenue per Expense Ratio
1.70
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
46.69%
Income Tax Rate
47.05%
EPS
0.2300000000
Balance Sheet Analysis
Current Ratio
2.03
Cash Ratio
0.98
Working Capital
$1.05B
Debt to Equity
1.63
Debt to Assets
55.50%
Equity Ratio
34.03%
Cash Flow Analysis
Operating Cash Flow Ratio
35.79%
Free Cash Flow Ratio
33.96%
CapEx to Revenue
1.83%
Dividends Paid
$191.18M
Stock Buybacks
$29.18M
Total Shareholder Returns
$220.37M
Cash Position Change
23.54%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
0.62%
Net Income
127.57%
EPS
111.50%
Operating Income
565.06%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
21.80%
Operating Cash Flow
-18.87%
Free Cash Flow
-18.57%
Balance Sheet Health
Assets
-1.85%
Debt
-1.54%
Book Value per Share
-2.21%
Inventory
100.00%
Shareholder Returns
Dividends per Share
-59.04%
Shares Outstanding
-0.40%
Long Term Trends
3Y Revenue/Share
18.62%
5Y Revenue/Share
-16.51%
3Y Dividend/Share
-78.54%
5Y Dividend/Share
-64.32%